Clinical trials: Prostate Cancer With Intermediate Risk
Prostate Cancer
Hyaluronic Acid for Hypofractionated Prostate Radiotherapy
The present Phase II study aims to assess the rates of late rectal toxicities of grade ≥ 2 after hypofractionated radiotherapy of prostate cancer of 62 Gy in 20 fractions of 3.1 Gy with an injection of hyaluronic acid (HA) in the…
- Trial name
- RPAH1 (NCT02165020)
- Testing
- Hyaluronic acid (Macrolane VRF 30®, Q-MED)
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
A First Step Towards Ultra-hypofractionation for Unfavourable Intermediate and High-risk Prostate Cancer
This study aims to make a first step towards ultra-hypofractionation for high-risk prostate cancer by proving the technical feasibility of margin reduction of the seminal vesicles by combining the intra-fraction fiducial tracking…
- Trial name
- UPRATE (NCT05361902)
- Testing
- Adaptive radiotherapy according to UPRATE protocol
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Erasmus Medical Center
Prostate Cancer, Sexual Dysfunction
Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Intensity-modulated radiation therapy (radiation directed at the tumor more precisely than in standard radiation therapy) may reduce damage to healthy…
- Conditions
- Prostate Cancer, Sexual Dysfunction, Sexuality and Reproductive Issues
- Trial name
- NCT00084552
- Testing
- radiation therapy
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Fox Chase Cancer Center
Low-to-intermediate-risk Prostate Carcinoma
Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy With SPACEOAR TM for Patients With Low-to-intermediate Risk Localized Prostate Cancer (DESAR-L)
A single institution with a single group, a phase II study, low- and medium-risk studies performed after biodegradable substance injection prostate cancer dosage increase.
- Trial name
- DESAR-L (NCT06461819)
- Testing
- Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase.
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Medical Center
Prostate Cancer, Adenocarcinoma of the Prostate
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
The first technology is called high dose rate brachytherapy. Brachytherapy is sometimes called internal radiation therapy. High dose rate brachytherapy is a procedure that involves temporarily placing radioactive material inside…
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01655836
- Testing
- Brachytherapy, Stereotactic Body Radiation Therapy, Quality-of-life assessment
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Prostate Cancer
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate cancer growing beyond the prostate gland in men with favorable intermediate risk…
- Trial name
- MIRROR (NCT06074510)
- Testing
- Piflufolastat F 18 Intravenous Solution [PYLARIFY]
- Where
- 14 sites in United States
- Volunteers
- 274 people
- Sponsor
- Lantheus Medical Imaging
Prostate Cancer (Adenocarcinoma), Localized Prostate Cancer
68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy
Focal therapy is a minimally invasive treatment option for some men with localized prostate cancer. Unlike surgery or radiation, focal therapy treats only the area of the prostate containing clinically significant cancer, with…
- Trial name
- PSMA-FT (NCT07747493)
- Testing
- Gallium Ga 68 Gozetotide (68Ga-PSMA-11), Intervention Description: Integrated positron emission tomography/magnetic resonance imaging (PET/MRI) combines molecular imaging with high-resolution anatomical MRI to evaluate intraprostatic lesions
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University Health Network, Toronto
Intermediate Risk Prostate Cancer, Castration-resistant Prostate Cancer
VAccination in Early and ADvanced Prostate caNCEr
This is a clinical trial of a new treatment for prostate cancer that is a type of vaccine that could be a new way to treat cancer.
- Trial name
- ADVANCE (NCT03815942)
- Testing
- ChAdOx1-MVA 5T4 vaccine, Nivolumab Infusion [Opdivo]
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- University of Oxford
Prostate Cancer
Intraprostatic MAXimal Simultaneous Boost
This trial uses a type of radiotherapy called intensity modulated radiotherapy (IMRT), which is able to deliver the radiation to the prostate while delivering less dose to the surrounding normal organs compared with standard 3D…
- Trial name
- NCT00798837
- Testing
- Intraprostatic maximal simultaneous boost
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Single Fraction Real-time High-Dose-Rate Brachytherapy in Patients With Low and Intermediate Risk Prostate Cancer
High-dose rate brachytherapy (HDR-BT) is an advanced technology theorized to be more advantageous than LDR-BT and External Beam Radiotherapy (EBRT), to the patient himself, and in terms of resource allocation.
- Trial name
- SINFRA_PROST (NCT02342054)
- Testing
- MRI-TRUS fusion guided Single Frac HDR
- Where
- Spain
- Volunteers
- 49 people
- Sponsor
- Hospital de Cruces
Prostate Cancer
Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone
The hypothesis of the proposed study would be that, due to the six months of total androgen blockade, which would include neoadjuvant hormonal therapy for four months and concomitant hormonal therapy for two months with…
- Trial name
- PCS III (NCT00223145)
- Testing
- Radiotherapy 70 Gy, Radiotherapy 76 Gy, Androgen blockade
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- Abdenour Nabid
Prostate Cancer
Prospective Evaluation of Hypofractionated Stereotactic RT Using CyberKnife for Patients With Prostate Cancer
The main purpose of study is to evaluate hypofractionated stereotactic radiotherapy (SBRT) using CyberKnife for Patients with low and intermediate risk of progression prostate cancer.
- Trial name
- CYBERPROST (NCT03225235)
- Testing
- SBRT
- Where
- Poland
- Volunteers
- 600 people
- Sponsor
- The Greater Poland Cancer Centre
Prostate Cancer
A Pan-Canadian, Investigator Initiated Clinical Trial With Focal IRE Directed to Intermediate-Risk Prostate Cancer
The goal of this clinical trial is to investigate the safety and efficacy of Irreversible Electroporation (IRE) using NanoKnife technology in patients with intermediate-risk prostate cancer.
- Trial name
- WIRED (NCT06451445)
- Testing
- Irreversible Electroporation (NanoKnife)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00547339
- Testing
- stereotactic body radiation therapy (SBRT)- 45 Gy, stereotactic body radiation therapy (SBRT) - 47.5 Gy, stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1)
- Where
- 5 sites in United States
- Volunteers
- 94 people
- Sponsor
- University of Texas Southwestern Medical Center
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
This phase I trial studies the side effects and best way to give enzalutamide, radiation therapy, and hormone therapy in treating patients with intermediate or high-risk prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT02023463
- Testing
- Enzalutamide, Goserelin acetate, Leuprolide acetate
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Thomas Jefferson University
Prostatic Neoplasm
HDR Brachytherapy Plus Stereotactic Ablative Prostate Radiotherapy for Patients With Intermediate and High-risk Prostate Cancer
Dose escalation is nowadays a standard strategy in radiotherapy for prostate cancer. Besides, it is believed that due to the radiobiology characteristics of prostate cells (low alpha/beta ratio), the delivery of higher radiation…
- Trial name
- BRAchySABR (NCT04523896)
- Testing
- Real time High-Dose-Rate prostate brachytherapy in combination with stereotactic prostate radiotherapy
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- David Büchser
Prostate Cancer
Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer
The purpose of this study is to test the safety and side effects "of "ultra-hypofractionated" radiation therapy when used after brachytherapy (radiation implants).
- Trial name
- NCT02280356
- Testing
- external beam radiation therapy, brachytherapy, questionnaires
- Where
- 6 sites in United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer
This phase I trial studies the side effects and best dose of multitargeted tyrosine kinase inhibitor PLX3397 (PLX3397) when given together with radiation therapy and antihormone therapy in treating patients with prostate cancer…
- Conditions
- Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
- Trial name
- NCT02472275
- Testing
- Antiandrogen Therapy, Laboratory Biomarker Analysis, Multitargeted Tyrosine Kinase Inhibitor PLX3397
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer
External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer
Primary Objective: To assess the possible improvement in prostate specific antigen (PSA) outcome of short course androgen suppression therapy in conjunction with dose-escalation intensity modulated radiation therapy (IMRT), 3D…
- Trial name
- NCT00388804
- Testing
- Radiation Therapy, Bicalutamide, Leuprolide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Prostatic Neoplasms, Prostatic Diseases
Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer
This study provides expanded access to radiotracer Gallium 68 (68Ga)-prostate-specific membrane antigen (PSMA)-HBED-CC (68Ga-PSMA-11) with Positron Emission Tomography (PET) imaging for participants with intermediate and high…
- Conditions
- Prostatic Neoplasms, Prostatic Diseases, Prostate Cancer, Prostate Cancer Metastatic
- Trial name
- NCT04452136
- Testing
- 68GA PSMA-HBED-CC
- Where
- United States
- Sponsor
- Jeanne Link